Helping Pharma Maximize the Potential of Pharmacogenomics - Diagnostic Solutions from DxS

By  

Pharmaceutical & Diagnostic Innovation, Vol. 2, Iss. 4, 2004-09 ,pp. : 13-17

Adis International

Access to resources Recommend Favorite

Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries

By Kaufmann Gilbert R   Smith Don   Bucher Heiner C   Phanuphak Praphan   Sendi Pedram P   Mbidde Edward K   Cooper David A   Battegay Manuel  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 9, 2002-09 ,pp. : 1303-1313

Informa Healthcare

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A   Veenstra David   Bebber Stephanie Van   Sakowski Julie  

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV –– Breakout Session 1

By Armstrong Martin   Bromley Christina   Cohen Nadine   Hunt Christine M   O’’Neill Robert   Power Aidan  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 117-125

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 3, 2009-09 ,pp. : 149-157

Bentham Science Publishers

Access to resources Recommend Favorite